Resultats de la cerca - Elisabeth I. Heath

Refinar resultats
  1. 1
    Angiogenesis inhibitors in the treatment of prostate cancer

    Angiogenesis inhibitors in the treatment of prostate cancer per Clara Hwang, Elisabeth I. Heath

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Prostate cancer dormancy and recurrence

    Prostate cancer dormancy and recurrence per Frank C. Cackowski, Elisabeth I. Heath

    Publicat 2021
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes

    Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes per Dejuan Kong, Seema Sethi, Yiwei Li, Wei Chen, Wael Sakr, Elisabeth I. Heath, Fazlul H. Sarkar

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinu... per Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette J. Wozniak

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer

    Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer per Lauren M. Hamel, Louis A. Penner, Terrance L. Albrecht, Elisabeth I. Heath, Clement K. Gwede, Susan Eggly

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Galectin-3: a possible complementary marker to the PSA blood test

    Galectin-3: a possible complementary marker to the PSA blood test per Vitaly Balan, Yi Wang, Pratima Nangia‐Makker, Dhonghyo Kho, Madhuri Bajaj, Daryn Smith, Lance K. Heilbrun, Avraham Raz, Elisabeth I. Heath

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis

    Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis per M. Katie Conley‐LaComb, Louie Semaan, Rajareddy Singareddy, Yanfeng Li, Elisabeth I. Heath, Seongho Kim, Michael L. Cher, Sreenivasa R. Chinni

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

    Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial per Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Primo N. Lara, Christopher Ruel, Gurkamal Chatta, Elisabeth I. Heath, David I. Quinn, David R. Gandara

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients

    Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients per Amitabh Chak, Marcia I. Canto, Gregory S. Cooper, Gerard Isenberg, Joseph Willis, Nathan Levitan, Julie Clayman, Arlene A. Forastiere, Elisabeth I. Heath, Michael Sivak

    Publicat 2000
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy per Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth I. Heath, Joseph A. Fontana, Ulka N. Vaishampayan

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Prostate Tumor Cell–Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms

    Prostate Tumor Cell–Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms per Mackenzie K. Herroon, Jonathan D. Diedrich, Erandi Rajagurubandara, Carly Martin, Krishna Rao Maddipati, Seongho Kim, Elisabeth I. Heath, James G. Granneman, Izabela Podgorski

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Smartphone apps for cancer: A content analysis of the digital health marketplace

    Smartphone apps for cancer: A content analysis of the digital health marketplace per Deborah H. Charbonneau, Shonee Hightower, Anne Katz, Ke Zhang, Judith Abrams, Nicole Senft, Jennifer Beebe‐Dimmer, Elisabeth I. Heath, Tara Eaton, Hayley S. Thompson

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Racial Disparities in the Molecular Landscape of Cancer

    Racial Disparities in the Molecular Landscape of Cancer per Elisabeth I. Heath, Filipa Lynce, Joanne Xiu, Angela Ellerbrock, Sandeep K. Reddy, Elias Obeid, Stephen V. Liu, Aliccia Bollig‐Fischer, Duška Šeparović, Ari M. Vanderwalde

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

    A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 per Naomi B. Haas, Xinyi Lin, Judith Manola, Michael Pins, Glenn Liu, David F. McDermott, David M. Nanus, Elisabeth I. Heath, George Wilding, Janice P. Dutcher

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer

    Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer per Iftekhar Ahmad, Jeffrey D. Forman, Fazlul H. Sarkar, Gilda G. Hillman, Elisabeth I. Heath, Ulka N. Vaishampayan, Michael L. Cher, Fundagül Andiç, Peter J. Rossi, Ömer Küçük

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

    A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate canc... per Manish Thakur, Lance K. Heilbrun, Shijie Sheng, Mark N. Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka N. Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman, Daryn Smith, Elisabeth I. Heath

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer per Anthony V. Serritella, Daniel H. Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph D. Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial

    Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial per Elisabeth I. Heath, Marcia I. Canto, Steven Piantadosi, Elizabeth A. Montgomery, W.M. Weinstein, James G. Herman, Andrew J. Dannenberg, Vincent W. Yang, Albert O. Shar, Ernest T. Hawk, Arlene A. Forastiere

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

    Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors per Patricia LoRusso, Martin J. Edelman, S. Bever, Karen Forman, MaryJo Pilat, Mary Flanagan Quinn, Jing Li, Elisabeth I. Heath, Lisa Malburg, Patrick Klein, Christopher P. Leamon, Richard A. Messmann, Edward A. Sausville

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    The current state of molecular testing in the treatment of patients with solid tumors, 2019

    The current state of molecular testing in the treatment of patients with solid tumors, 2019 per Wafik S. El‐Deiry, Richard M. Goldberg, Heinz‐Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I. Heath, Surasak Phuphanich, Edward Kim, Andrew Brenner, John L. Marshall

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:

Eines de cerca: